Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study

Daubioul, Catherine; Horsmans, Yves; Lambert, Philippe; Danse, Étienne; Delzenne, Nathalie M.

doi:10.1038/sj.ejcn.1602127

Cited by 181 publications

(134 citation statements)

References 16 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…This merits further investigation. While the doses used in animal studies are not directly transposable to human nutrition, several reports have demonstrated that ingestion of fructo-oligosaccharides at the dose of 5 to 20 g/day are sufficient to promote prebiotic [37][38][39][40] and physiological effects [41][42][43][44].…”

Section: Discussionmentioning

confidence: 99%

Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia

et al. 2007

View full text Add to dashboard Cite

Aims/hypothesis Recent evidence suggests that a particular gut microbial community may favour occurrence of the metabolic diseases. Recently, we reported that high-fat (HF) feeding was associated with higher endotoxaemia and lower Bifidobacterium species (spp.) caecal content in mice. We therefore tested whether restoration of the quantity of caecal Bifidobacterium spp. could modulate metabolic endotoxaemia, the inflammatory tone and the development of diabetes. Methods Since bifidobacteria have been reported to reduce intestinal endotoxin levels and improve mucosal barrier function, we specifically increased the gut bifidobacterial content of HF-diet-fed mice through the use of a prebiotic (oligofructose [OFS]). Results Compared with normal chow-fed control mice, HF feeding significantly reduced intestinal Gram-negative and Gram-positive bacteria including levels of bifidobacteria, a dominant member of the intestinal microbiota, which is seen as physiologically positive. As expected, HF-OFS-fed mice had totally restored quantities of bifidobacteria. HFfeeding significantly increased endotoxaemia, which was normalised to control levels in HF-OFS-treated mice. Multiple-correlation analyses showed that endotoxaemia significantly and negatively correlated with Bifidobacterium spp., but no relationship was seen between endotoxaemia and any other bacterial group. Finally, in HF-OFS-treated-mice, Bifidobacterium spp. significantly and positively correlated with improved glucose tolerance, glucose-induced insulin secretion and normalised inflammatory tone (decreased endotoxaemia, plasma and adipose tissue proinflammatory cytokines). Conclusions/interpretation Together, these findings suggest that the gut microbiota contribute towards the pathophysiological regulation of endotoxaemia and set the tone of inflammation for occurrence of diabetes and/or obesity. Thus, it would be useful to develop specific strategies for modifying gut microbiota in favour of bifidobacteria to prevent the deleterious effect of HF-diet-induced metabolic diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia

et al. 2007

View full text Add to dashboard Cite

show abstract

“…148 Lifestyle modification and dietary advice with a very modest 53,127 or even no-weight reduction 6,33,42 can result in changes in body fat depots and improvements in liver function test, 140,144 cytokines 83,109 and histology in NASH. 33,140,149 There are some in vitro studies or small trials on the effect of ketogenic, hypoenergetic diet, 144,145 specific diets rich in omega-3 polyunsaturated fatty acids 42,138,[149][150][151] or a short-chain oligofructose-enriched diet 42,152 that have shown improvement in liver enzyme and pathology in NAFLD patients.…”

Section: Weight Lossmentioning

confidence: 99%

Nonalcoholic fatty liver disease: a challenge for pediatricians

Widhalm

Ghods

2010

Int J Obes

View full text Add to dashboard Cite

Background: Nonalcoholic fatty liver disease (NAFLD) is the most common cause of pediatric liver disease. Its prevalence is related to the growing epidemic in childhood obesity during the past decades. At present, NAFLD and nonalcoholic steatohepatitis (NASH) are increasingly recognized worldwide. In spite of alarming trend in the epidemiology in pediatric field and growing risk of end stage liver disease, there is no significant advance in its diagnosis and treatment. Aim: To provide a detailed review for diagnosis and management of NAFLD and NASH. Methods: By using Pubmed to find review articles and relevant research. Results: The prevalence ranges from at least 3% in children overall to about 50% in obese children. The noninvasive biomarkers can be used to identify NAFLD/NASH patients. Diagnostic criteria based on biochemical and immunological indicators in the high-risk group of children could prevent about half of cases from receiving an invasive test. The pharmacological and surgical interventions have shown a growing role in pediatric NAFLD. Novel treatment modalities, such as probiotics, have hardly been studied. Conclusion: Early diagnosis by using noninvasive screening methods in high-risk groups is the most effective strategy against the NAFLD. The biology of early growth and development, including hepatic metabolism, may hold the key to pediatric NAFLD. Prevention of overweight children and childhood obesity is undoubtedly the best strategy for treating NAFLD.

show abstract

“…Oligofructose (OFS), an inulin-type fructans, were added to diet for patients with NASH in a pilot randomized double-blind study [118]. The results showed that OFS supplementation decreased serum ALT and AST levels significantly compared to that in placebo group.…”

Section: Gut Microbiota-targeted Therapy With Prebioticmentioning

confidence: 96%

“…Prebiotics exert benefits on host health by altering gut microbiota [116], and several lines of evidence have demonstrated that prebiotics benefits NAFLD prevention by modulating gut microbiota in both experimental and clinical studies [117,118].…”

Section: Gut Microbiota-targeted Therapy With Prebioticmentioning

confidence: 99%

Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Therapy

Ma¹,

Zhou²,

Li³

2017

Preprint

View full text Add to dashboard Cite

Gut microbiota play critical roles in development of obese-related metabolic diseases such as nonalcoholic fatty liver disease (NAFLD), type 2 diabetes, and insulin resistance, which highlighted the potential of gut microbiota-targeted therapies on these diseases. There are various ways that can manipulate gut microbiota including probiotics, prebiotics, synbiotics, antibiotics and some active components from herbal medicines. In this review, we first described the main roles of gut microbiota in mediating the development of NAFLD, and the advances in gut microbiota-targeted therapies in NAFLD in both the experimental and clinical studies, as well as the conclusions on the prospect of gut microbiotatargeted therapies in the future.

show abstract

Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study

Cited by 181 publications

References 16 publications

Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia

Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia

Nonalcoholic fatty liver disease: a challenge for pediatricians

Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Therapy

Contact Info

Product

Resources

About